DOCSLIB.ORG

Icahn School of Medicine at Mount Sinai, Series 2015A

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Icahn School of Medicine at Mount Sinai, Series 2015A Ratings: S&P: A- Moody’s: A3 (See “Ratings” herein) $512,410,000 DORMITORY AUTHORITY OF THE STATE OF NEW YORK ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI REVENUE BONDS, SERIES 2015A Dated: Date of Delivery Due: July 1, as shown on the inside cover Payment and Security: The Icahn School of Medicine at Mount Sinai Revenue Bonds, Series 2015A (the “Series 2015 Bonds”) are special obligations of the Dormitory Authority of the State of New York (“DASNY” or the “Authority”) payable solely from and secured by a pledge of certain payments to be made under the Loan Agreement, dated as of June 27, 2007, as previously amended and supplemented and as further supplemented by the Supplement No. 2 to Loan Agreement, dated as of May 13, 2015 (collectively, the “Loan Agreement”), each between the Icahn School of Medicine at Mount Sinai (formerly known as Mount Sinai School of Medicine of New York University) (the “Institution” or the “School”) and the Authority and all funds and accounts (except the Arbitrage Rebate Fund) authorized under the Mount Sinai School of Medicine of New York University Revenue Bond Resolution, adopted June 27, 2007 (the “Resolution”) and established under the Series 2015A Resolution Authorizing Up To $580,000,000 Icahn School of Medicine at Mount Sinai Revenue Bonds, Series 2015A, adopted May 13, 2015 (the “Series 2015 Resolution”). The Loan Agreement is a general obligation of the Institution and requires the Institution to pay, in addition to the fees and expenses of the Authority and the Trustee, amounts sufficient to pay the principal and Redemption Price of and interest on the Series 2015 Bonds, as such payments become due. The obligations of the Institution under the Loan Agreement to make such payments will be secured by a pledge of certain revenues of the Institution. Neither the Loan Agreement nor the Series 2015 Bonds are obligations of The Mount Sinai Hospital or The Mount Sinai Medical Center, Inc. The Series 2015 Bonds will not be a debt of the State of New York nor will the State be liable thereon. The Authority has no taxing power. Description: The Series 2015 Bonds will be issued as fully registered bonds in denominations of $5,000 or any integral multiple thereof. Interest (due January 1, 2016 and each July 1 and January 1 thereafter) will be payable by check or draft mailed to the registered owners of the Series 2015 Bonds at their addresses as shown on the registration books held by the Trustee or, at the option of a holder of at least $1,000,000 in principal amount of Series 2015 Bonds, by wire transfer to the holder of such Series 2015 Bonds, each as of the close of business on the fifteenth day of the month next preceding an interest payment date. The principal or Redemption Price of the Series 2015 Bonds will be payable at the principal corporate trust office of Manufacturers and Traders Trust Company, Buffalo, New York, the Trustee and Paying Agent or, with respect to Redemption Price, at the option of a holder of at least $1,000,000 in principal amount of Series 2015 Bonds, by wire transfer to the holders of such Series 2015 Bonds as more fully described herein. The Series 2015 Bonds will be issued initially under a Book-Entry Only System, registered in the name of Cede & Co., as nominee for The Depository Trust Company (“DTC”). Individual purchases of beneficial interests in the Series 2015 Bonds will be made in Book- Entry form (without certificates). So long as DTC or its nominee is the registered owner of the Series 2015 Bonds, payments of the principal and Redemption Price of and interest on such Series 2015 Bonds will be made directly to DTC or its nominee. Disbursement of such payments to DTC participants is the responsibility of DTC and disbursement of such payments to the beneficial owners is the responsibility of DTC participants. See “PART 3 - THE SERIES 2015 BONDS - Book-Entry Only System” herein. Redemption and Purchase in Lieu of Optional Redemption: The Series 2015 Bonds are subject to redemption and purchase in lieu of optional redemption prior to maturity as more fully described herein. Tax Matters: In the opinion of Orrick, Herrington & Sutcliffe LLP, Bond Counsel to the Authority, based upon an analysis of existing laws, regulations, rulings and court decisions, and assuming, among other matters, the accuracy of certain representations and compliance with certain covenants, interest on the Series 2015 Bonds is excluded from gross income for federal income tax purposes under Section 103 of the Internal Revenue Code of 1986 and is exempt from personal income taxes imposed by the State of New York and any political subdivision thereof (including The City of New York). In the further opinion of Bond Counsel, interest on the Series 2015 Bonds is not a specific preference item for purposes of the federal individual or corporate alternative minimum taxes, although Bond Counsel observes that such interest is included in adjusted current earnings when calculating corporate alternative minimum taxable income. Bond Counsel expresses no opinion regarding any other tax consequences related to the ownership or disposition of, or the amount, accrual or receipt of interest on, the Series 2015 Bonds. See “PART 12 - TAX MATTERS” herein. The Series 2015 Bonds are offered when, as and if issued. The offer of the Series 2015 Bonds may be subject to prior sale or withdrawn or modified at any time without notice. The offer is subject to the approval of legality by Orrick, Herrington & Sutcliffe LLP, New York, New York, Bond Counsel to the Authority, and to certain other conditions. Certain legal matters will be passed upon for the Institution by Beth Essig, Esq., its Executive Vice President and General Counsel and by its Special Counsel, Winston & Strawn LLP, New York, New York, and for the Underwriters by their Counsel, Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., New York, New York, and the Law Offices of Joseph C. Reid, P.A., New York, New York. The Authority expects to deliver the Series 2015 Bonds in definitive form in New York, New York, on or about August 20, 2015. Citigroup Goldman, Sachs & Co. Academy Securities, Inc. BofA Merrill Lynch Fidelity Capital Markets J.P. Morgan Morgan Stanley Ramirez & Co., Inc. Rice Financial Products Company Stifel TD Securities August 7, 2015 $512,410,000 DORMITORY AUTHORITY OF THE STATE OF NEW YORK ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI REVENUE BONDS, SERIES 2015A Due Interest CUSIP July 1 Amount Rate Yield Number** 2016 $12,620,000 2.500% 0.510% 64990BPN7 2017 9,960,000 3.000 0.940 64990BPP2 2018 10,250,000 5.000 1.300 64990BPQ0 2019 10,765,000 5.000 1.540 64990BPR8 2020 11,305,000 4.000 1.850 64990BPS6 2021 10,895,000 5.000 2.210 64990BPT4 2022 11,430,000 5.000 2.560 64990BPU1 2023 11,985,000 5.000 2.800 64990BPV9 2024 12,620,000 5.000 2.960 64990BPW7 2025 17,670,000 5.000 3.090 64990BPX5 2026 18,515,000 5.000 3.240* 64990BPY3 2027 19,400,000 5.000 3.370* 64990BPZ0 2028 20,330,000 5.000 3.450* 64990BQA4 2029 21,355,000 5.000 3.530* 64990BQB2 2030 22,105,000 5.000 3.590* 64990BQC0 2031 23,215,000 5.000 3.680* 64990BQD8 2032 24,380,000 5.000 3.730* 64990BQE6 2033 25,595,000 5.000 3.770* 64990BQF3 2034 26,875,000 5.000 3.810* 64990BQG1 2035 28,215,000 5.000 3.830* 64990BQH9 2036 29,625,000 4.000 4.090 64990BQM8 $64,325,000 5.00% Term Bonds maturing July 1, 2040 to Yield* 3.94% CUSIP**: 64990BQJ5 $25,000,000 4.00% Term Bonds maturing July 1, 2040 to Yield 4.14% CUSIP**: 64990BQL0 $43,975,000 5.00% Term Bonds maturing July 1, 2045 to Yield* 4.02% CUSIP**: 64990BQK2 * Priced to the first optional redemption date, July 1, 2025. ** CUSIP data herein are provided by Standard &Poor’s, CUSIP Service Bureau, a division of The McGraw-Hill Companies, Inc. CUSIP numbers have been assigned by an independent company not affiliated with the Authority and are included solely for the convenience of the holders of the Series 2015 Bonds. The Authority is not responsible for the selection or uses of these CUSIP numbers, and no representation is made as to their correctness on the Series 2015 Bonds or as indicated above. The CUSIP number for a specific maturity is subject to being changed after the issuance of the Series 2015 Bonds as a result of various subsequent actions including, but not limited to, a refunding in whole or in part of such maturity or as a result of the procurement of secondary market portfolio insurance or other similar enhancement by investors that is applicable to all or a portion of certain maturities of the Series 2015 Bonds. (i) No dealer, broker, salesperson or other person has been authorized by DASNY, the Institution or the Underwriters to give any information or to make any representations with respect to the Series 2015 Bonds, other than the information and representations contained in this Official Statement. If given or made, any such information or representations must not be relied upon as having been authorized by DASNY, the Institution or the Underwriters. This Official Statement does not constitute an offer to sell or the solicitation of an offer to buy nor shall there be a sale of the Series 2015 Bonds by any person in any jurisdiction in which it is unlawful for such person to make such offer, solicitation, or sale.
Load more

Recommended publications
  • Mount Sinai Vascular Surgeons Among First in Nation to Treat Complex Aortic Aneurysm with New Device
    A PUBLICATION OF THE MOUNT SINAI HEALTH SYSTEM May 2 - 22, 2016 Mount Sinai Vascular Surgeons Among First in Nation To Treat Complex Aortic Aneurysm With New Device Physicians at The Mount Sinai Hospital were among the first in the nation to implant an investigational device, a fabric and metal mesh tube known as a stent graft, as part of a clinical trial to treat aneurysms located in the thoracic/abdominal area of the aorta. Mount Sinai is one of only six institutions in the nation granted approval by the U.S. Food and Drug Administration to test the safety and initial feasibility of the device in patients. The stent graft is used to strengthen the inner lining of the aorta—the main artery that carries blood from the heart to organs—in patients where the aortic walls have weakened and caused a balloon-type bulge known as an aneurysm to grow. Once implanted, the device serves to direct blood From left: Rami O. Tadros, MD, FACS; James F. McKinsey, MD, FACS; and Michael L. Marin, flow away from the aneurysm, causing MD, FACS, are using a new-generation implantable device to treat complex thoracoabdominal it to shrink in size. If not repaired, the aortic aneurysms. continued on page 2 › Mammograms May Reveal Early Signs of Heart Disease Routine mammograms used for the 70 percent of mammograms with breast early detection of breast cancer may also arterial calcification (BAC) correlated with provide women with an early warning the presence of coronary artery calcium of cardiovascular disease, according to (CAC). Calcium deposits in the coronary a recent study led by Laurie Margolies, arteries can narrow arteries and increase MD, Associate Professor of Radiology at the risk of heart attack.
    [Show full text]
  • In Vivo Quantitation of Regional Cerebral Blood Flow in Glioma and Cerebral Infarction: Validation of the Hipdm­ SPECT Method
    572 In vivo Quantitation of Regional Cerebral Blood Flow in Glioma and Cerebral Infarction: Validation of the HIPDm­ SPECT Method Burton Drayer ," 2 Ronald Jaszczak,' Allan Friedman,3 Robert Albright,'·2 Hank Kung,4 Kim Greer,' Michael Lischko,' Neil Petry,' and Edward Coleman' todine-123 labeled hydroxyiodopropyldiamine (HIPDm) is a a visual or quantitati ve analysis of brain distribution is sufficient for diffusible indicator with an 85% -90% extraction fraction and defining an abnormality when a focal pathologic process is present, stable retention in the brain for more than 2 hr. Equilibrium­ an absolute valu e for rCBF is necessary if studies are to be com­ phase imaging and quantitation using single-photon emission pared in different stages of disease or an analysis is to be made of computed tomographic (SPECT) scanning defined a distribution diffuse, bilaterall y symmetric pathologic processes (e.g., Alzheimer of HIPDm in proportion to regional cerebral blood flow (rCBF). disease, metaboli c encephalopathy). Studies in calves affirmed a close correspondence (r = 0.97) in calculated rCBF between HIPDm and microspheres using the tissue deposition-arterial input function microsphere methodol­ Materials and Methods ogy. Using this same mathematical analysis in vivo, reproducible Isotope Detection rCBF data within the expected range of normal were obtained on repeated studies in the same nonhuman primate. With a The Duke-Siemens SPECT system [14, 15] con sists of two op­ diffuse encephalopathy secondary to subarachnoid blood, a posing large-field-of-view (LFOV) gamma scintillation cameras bilaterally symmetric decrease in rCBF was present. A prominent mounted on a rotatabl e gantry with each head rotating through focal decrease in HIPDm accumulation and calculated rCBF was 360 0 in 2- 26 min .
    [Show full text]
  • Artificial Intelligence Platform Screens for Acute Neurological Illnesses 13 August 2018
    Artificial intelligence platform screens for acute neurological illnesses 13 August 2018 for detecting a wide range of acute neurologic events and to demonstrate a direct clinical application. Researchers used 37,236 head CT scans to train a deep neural network to identify whether an image contained critical or non-critical findings. The platform was then tested in a blinded, randomized controlled trial in a simulated clinical environment where it triaged head CT scans based on severity. The computer software was tested for how quickly it could recognize and provide notification versus the time it took a radiologist to notice a disease. The average time for the computer algorithm to preprocess an image, run its inference method, and, if necessary, raise an alarm was 150 times shorter than for physicians to read the image. This study used "weakly supervised learning approaches," which built on the research team's Credit: CC0 Public Domain expertise in natural language processing and the Mount Sinai Health System's large clinical datasets. Dr. Oermann says the next phase of this research will entail enhanced computer labeling of CT scans An artificial intelligence platform designed to and a shift to "strongly supervised learning identify a broad range of acute neurological approaches" and novel techniques for increasing illnesses, such as stroke, hemorrhage, and data efficiency. Researchers estimate the goal of re- hydrocephalus, was shown to identify disease in engineering the system with these changes will be CT scans in 1.2 seconds, faster than human accomplished within the next two years. diagnosis, according to a study conducted at the Icahn School of Medicine at Mount Sinai and "The expression 'time is brain' signifies that rapid published today in the journal Nature Medicine.
    [Show full text]
  • Local Cerebral Blood Flow Measured by CT After Stable Xenon Inhalation
    213 Local Cerebral Blood Flow Measured by CT After Stable Xenon Inhalation John Stirling Meyer 1 A safe, practical, clinically applicable, noninvasive method for measuring local L. Anne Hayman2 cerebral blood flow (LCBF) using inert xenon (XeS) and a 60 sec CT scanner has been Masahiro Yamamoto 1 developed in the baboon. Direct measurement of expired Xes concentration after short Fumihiko Sakai1 inhalation (4-7 min) of 40% Xes and the use of computer-programmed autoradiographic 1 formulas allow accurate, reproducible measurements of LCBF using serial 60 sec scans Shinji Nakajima 3 of regions as small as 0.04 cm • LCBF measurements are possible with a Single 1 min scan. The method reduces radiation exposure, obviates a costly fourth-generation scanner, avoids anesthetic effects of Xes, and reduces the 30 min/ scan saturation period. It is less expensive than emission tomography and minimizes problems of overlap and Compton scatter inherent in 133Xe and positron-emission blood flow measurements. Regions of zero perfusion are demonstrable in three dimensions. Tissue solubility and partition coefficients, as well as LCBF, are measured in vivo with high resolution and reproducibility so that minor regional changes in physical properties of tissue that alter solubility are measured. These enhance the potential clinical usefulness of CT scanning. Measurement of cerebral blood flow using stable xenon (XeS) computed tom­ ographic (CT) scanning has been largely confined to animal models for several reasons [1-6]. Anesthetic properties of high concentrations of Xes, expense, high radiation dosage from excessive serial scans, time, and personnel necessary for prolonged studies involving immobilized patients have limited clinical imple­ mentation.
    [Show full text]
  • CURRICULUM VITAE JORGE L. GAMBA, MD Office
    Drs. Mori, Bean & Brooks, P.A. 3599 University Blvd., S. Building 300 Jacksonville, Florida 32216 904.399.5550 Fax 904.346.4334 www.mbbradiology.com PRACTICE INCLUDES: • DIAGNOSTIC RADIOLOGY CURRICULUM VITAE • INTERVENTIONAL RADIOLOGY • NEURORADIOLOGY JORGE L. GAMBA, MD • NUCLEAR MEDICINE • WOMEN'S IMAGING Office: Drs. Mori, Bean and Brooks, P.A. 3599 University Blvd. S., Bldg 300 Jacksonville, FL 32216 Work Phone: (904) 399-5550 [email protected] Professional Goal: To participate in a practice which provides personalized quality health care to the community utilizing state of the art diagnostic and interventional imaging modalities. To be involved in teaching and education at a resident and staff level. Present Capacity: Attending staff radiologist at Baptist Medical Center, Orange Park Medical Center, Memorial Hospital and Baptist Medical Center–Beaches, Baptist Medical Center-Nassau, and Baptist CLIFFORD H. SPOHR, M.D. Medical Center–South with special interest and expertise in GRADY C. STEWART, JR., M.D. KURT W. MORI, M.D. neuroradiology, magnetic resonance imaging (MRI), and STEVE A. SHIRLEY, M.D. FRANK W. SANCHEZ, M.D. interventional radiology. JORGE L. GAMBA, M.D. BARBARA L. SHARP, M.D. R. STEPHEN SURRATT, M.D. Ex-Chairman of Department of Radiology of Baptist Medical JAMIE T. SURRATT, M.D. PATRICK O. GORDON, M.D. Center. Ex-Director of Special Procedures, Baptist Medical CHRISTINE A.J. GRANFIELD, M.D. Center. Ex-Chairman of Department of Radiology, Baptist SUDHA BOGINENI-MISRA, M.D. MICHAEL J. BORBELY, M.D. Medical Center–Beaches. DENNIS W. WULFECK, M.D. JEFFREY H. WEST, M.D. SCOTT L. KALTMAN, M.D.
    [Show full text]
  • Original (PDF)
    Translational & M olecular I maging I nstitute 6th Annual Symposium April 22, 2016 New York, NY Table of Contents Symposium Schedule ………………………………………………….……………………………………………………………………..............……… 1 Message from the Director ……………………………………………..………………..…………….……..…………………….....…………........... 3 Translational and Molecular Imaging Institute ……………………………………………………………………………………….................… 5 Human Imaging Core ……………………………………………………………………………………………………………................……….. 9 Small Animal Imaging Core …………………………………………………………………………………………………...............………… 13 TMII Research Laboratories ………………………………………………………………………………………................…………………… 16 Biographies of Invited Speakers ……………………………...…………………………………………………………………………...........…....... 21 Zahi A. Fayad, PhD …………………………………………………………..…………………………………………………………...........……….. 23 Dennis S. Charney, MD …………………………………………..………………………..……………………………………............…………... 25 Burton P. Drayer, MD …………………………………………..………………………..……………………………………............…………... 27 Bruce Fischl, PhD ..................………………………………………………….…………………………………………..………….........….... 29 Julie Price, PhD …....………………………………………………………………………………………………………………………............... 31 Mark Griswold, PhD ………………………………………………………………………………………………………...............……………... 33 Anna Moore, PhD ………….…………………………………………………………………………………...............…………………….......... 35 Debiao Li, PhD .................………………………………………………………………………………………………………...............……... 37 Abstracts Selected for Oral Presentation ………………………………………………………………………………………………................ 39 Neuroimaging
    [Show full text]
  • May 29Th, 2014 New York Academy Registration Still Open! of Medicine
    Location: May 29th, 2014 New York Academy Registration Still Open! of Medicine Opening Remarks Cardiovascular Imaging Zahi A. Fayad, PhD Sebastian Kozerke, PhD Director, TMII Beyond Nyquist – Accelerated Icahn School of Medicine at Mount Sinai Cardiovascular Magnetic Resonance Imaging Dennis Charney, MD University of Zürich Dean, Icahn School of Medicine at Mount Sinai Cancer & Body Imaging Andrew Rosenkrantz, MD Keynote Prostate Cancer: Defining a John Darrell Van Horn, New Clinical Paradigm Through PhD Multi-parametric MRI The Mapping of Structural and New York University Connectomic Alteration in Traumatic Brain Injury Nanomedicine University of Southern California C. Shad Thaxton, MD, PhD Therapeutic Opportunities Neuroimaging for High Density Lipoprotein Jon Shah, PhD Nanoparticles Multimodal Simultaneous Imaging: Northwestern University Advances in MR-PET-EEG 3T and 9.4T in Humans Closing Remarks Forschungszentrum Juelich GmbH Burton Drayer, MD Chair, Radiology Icahn School of Medicine at Mount Sinai For open registration and more information visit: tmii.mssm.edu/symposium Translational and Molecular Imaging Institute - TMII Leon and Norma Hess Center for Science and Medicine 1470 Madison Avenue (between 101st and 102nd St) - 1st Floor New York, NY 10029 SYMPOSIUM SCHEDULE New York Academy of Medicine – May 29th, 2014 7:00am – 8:00am Registration (2nd floor)/Poster Set-up (Room 21) OPENING REMARKS 8:00am – 8:15am Zahi A. Fayad, PhD (Director, Translational & Molecular Imaging Institute) 8:15am – 8:30am Dennis Charney, MD (Dean, Icahn School of Medicine at Mount Sinai) KEYNOTE ADDRESS – Moderator: Rita Goldstein, PhD 8:30am – 9:30am John Darrell Van Horn, PhD (University of Southern California, Los Angeles, CA) “The Mapping of Structural and Connectomic Alteration in Traumatic Brain Injury” SESSION I – NEUROIMAGING –Moderator: Priti Balchandani, PhD 9:30am – 10:15am N.
    [Show full text]
  • Artificial Intelligence Platform Screens for Acute Neurological Illnesses at Mount Sinai
    Artificial intelligence platform screens for acute neurological illnesses at Mount Sinai eurekalert.org/pub_releases/2018-08/tmsh-aip080718.php Public Release: 13-Aug-2018 The study's findings lay the framework for applying deep learning and computer vision techniques to radiological imaging The Mount Sinai Hospital / Mount Sinai School of Medicine (New York - August 13, 2018) An artificial intelligence platform designed to identify a broad range of acute neurological illnesses, such as stroke, hemorrhage, and hydrocephalus, was shown to identify disease in CT scans in 1.2 seconds, faster than human diagnosis, according to a study conducted at the Icahn School of Medicine at Mount Sinai and published today in the journal Nature Medicine. "With a total processing and interpretation time of 1.2 seconds, such a triage system can alert physicians to a critical finding that may otherwise remain in a queue for minutes to hours," says senior author Eric Oermann, MD, Instructor in the Department of Neurosurgery at the Icahn School of Medicine at Mount Sinai. "We're executing on the vision to develop artificial intelligence in medicine that will solve clinical problems and improve patient care." This is the first study to utilize artificial intelligence for detecting a wide range of acute neurologic events and to demonstrate a direct clinical application. Researchers used 37,236 head CT scans to train a deep neural network to identify whether an image contained critical or non-critical findings. The platform was then tested in a blinded, randomized controlled trial in a simulated clinical environment where it triaged head CT scans based on severity.
    [Show full text]
  • Departments of Neurology and Neurosurgery
    Departments of Neurology and Neurosurgery SPECIALTY REPORT | 2019 mountsinai.org Time ~12 mins to MD notification ~27 mins to MD notification Standard first-in, first-out work queue 177s per case CNN processing at high sensitivity Re-queuing Prioritized work queue ~3 mins to MD notification ~12 mins to MD notification A sample work queue containing 10 cases demonstrating the system in deployment. Mount Sinai Health System researchers have designed an automated deep learning Study Shows How neural network that can detect acute neurological diseases such as stroke, hemorrhage, and hydrocephalus within minutes, enabling earlier intervention that can preserve Artificial Intelligence neurological function and improve patient outcomes. Helped Detect Acute This is the first study to use artificial intelligence (AI) to identify acute neurological disease and thus demonstrate a direct clinical application of AI in a randomized controlled trial. Cases Earlier Using 37,236 head CT scans, researchers trained a 3D conventional neural network (3D-CNN) to determine whether an image contained critical or non-critical findings, thus enabling triaging and queuing of radiology workflow for physician review based on the probability of acute neurological illness. Researchers subsequently conducted a randomized, double-blinded, prospective trial to assess the ability and quickness of continued on page 6 › Advancing the Use of Novel Technology in the OR Core, where there has been considerable investment in next-generation microscopy. Mount Sinai became one of the first health systems nationwide to use the ZEISS KINEVO® 900 microscope, a surgeon- driven robotic visualization system that not only streams 3D optical, navigation, and simulation information in 4K resolution into the microscope’s eyepiece, but also projects those data on large monitors in the operating room.
    [Show full text]
  • Complete Issue (PDF)
    FEBRUARY 2014 THE JOURNAL OF DIAGNOSTIC AND VOLUME 35 INTERVENTIONAL NEURORADIOLOGY NUMBER 2 WWW.AJNR.ORG White matter damage in boxers and martial arts fighters Perivascular spaces in the anterior temporal lobes Hyperattenuated lesions after mechanical recanalization in acute stroke Official Journal ASNR • ASFNR • ASHNR • ASPNR • ASSR The New Standard of Excellence, Redefining Compliant balloon designed for reliable vessel occlusion yet conforms to vessel anatomy Scepter C® MicroVention, Inc. Worldwide Headquarters PH +1.714.247.8000 1311 Valencia Avenue Tustin, CA 92780 USA MicroVention United Kingdom PH +44 (0) 191 258 6777 MicroVention Europe, S.A.R.L. PH +33 (1) 39 21 77 46 For more information or a product demonstration, MicroVention Deutschland GmbH PH +49 211 210 798-0 contact your local MicroVention representative: Web microvention.com Deliverability Versatility and Control Occlusion Balloon with Xtra Compliant .014” Guidewire Compatibility balloon conforms to – Maximizing the utility of a unique coaxial shaft, Scepter Occlusion Balloon Catheter incorporates many extremely complex new product features anatomies where – Balloon diameters range from 2mm to 6mm neck coveracoveragege is Key Compatible Agents more challenchallengingging – Compatible for use with dimethyl sulfoxide (DMSO) – Compatible for use with diagnostic agents and liquid embolic agents such as Onyx® Liquid Embolic System (FDA and CE approved) Scepter XC® Compatible with MICROVENTION, Scepter C, Scepter XC and Traxcess are registered trademarks of MicroVention, Inc. Onyx Liquid Embolic System is a registered trademark of Covidien. t4DJFOUJmDBOEDMJOJDBMEBUBSFMBUFEUPUIJTEPDVNFOUBSFPOmMFBU.JDSP7FOUJPO *OD3FGFS to Instructions for Use for additional information. Federal (USA) law restricts this device for sale by or on the order of a physician.
    [Show full text]
  • Mount Sinai Experience in Migrating from Radioactive Irradiators to X-Ray Irradiators for Blood and Medical Research Applications
    MOUNT SINAI EXPERIENCE IN MIGRATING FROM RADIOACTIVE IRRADIATORS TO X-RAY IRRADIATORS FOR BLOOD AND MEDICAL RESEARCH APPLICATIONS New York / September 2018 Table of Contents Page Letter from Mount Sinai Leadership 3 Acknowledgement 4 Summary of Previous Studies 5 Radiobiology and Depth Dose Measurements. Kamen J, Hill C 7 Comparison of X-ray vs Cs irradiator for producing fibroblasts used to grow B cell 13 lines in vitro. Isaiah Peoples, Tina Yao, Denise Peace, Peter S. Heeger Comparison of X-ray vs Cs irradiator for the efficiency of transfer CD4+ T cells into 20 B6 mice. Lili Chen, Zhengxiang He, Glaucia Furtado & Sergio Lira X-ray irradiation, bone marrow transplantation, and composition of the donor- 24 reconstituted murine immune system. Verena van der Heide, Bennett Davenport and Dirk Homann Comparative analysis of X-ray vs 137Cs radiation in zebrafish embryos: cell death, 31 organismal radiosensitivity and p53-dependence. Renuka Raman, Yuanyuan Li and Samuel Sidi Comparison of effect of X-ray and Cs irradiation on PBMC in vitro. Naoko Imai, 39 Sacha Gnjatic Comparison of X-ray vs Cs-137 irradiation for producing mitotically-inactivated 44 mouse embryonic fibroblasts to grow mouse embryonic stem (ES) cells. Nika Hines, Pedro Sanabria and Kevin Kelley X-Ray Irradiation Is the Preferred Method of Irradiation for Tumor Cell Immunization. 47 Ananda Mookerjee and Thomas Weber Cancer Cell Organoid Core Experience in Transition to the X-ray irradiator. Pamela 49 Cheung, Ph.D. and Stuart Aaronson, M.D. Investigating the enhancing effects of combining radiation with oncolytic Newcastle 50 Disease Virus (NDV) therapy in a murine melanoma model.
    [Show full text]
  • Magnetic Resonance Imaging of Brain Iron
    373 Magnetic Resonance Imaging of Brain Iron Burton Drayer" 2 A prominently decreased signal intensity in the globus pallidum, reticular substantia Peter Burger nigra, red nucleus, and dentate nucleus was routinely noted in 150 consecutive individ­ Robert Darwin' uals on T2-weighted images (SE 2000/100) using a high field strength (1.5 T) MR system. Stephen Riederer' This MR finding correlated closely with the decreased estimated T2 relaxation times Robert Herfkens' and the sites of preferential accumulation of ferric iron using the Perls staining method on normal postmortem brains. The decreased signal intensity on T2-weighted images G. Allan Johnson' thus provides an accurate in vivo map of the normal distribution of brain iron. Perls stain and MR studies in normal brain also confirm an intermediate level of iron distribution in the striatum, and still lower levels in the cerebral gray and white matter. In the white matter, iron concentration is (a) absent in the most posterior portion of the internal capsule and optic radiations, (b) higher in the frontal than occipital regions, and (c) prominent in the subcortical " U" fibers, particularly in the temporal lobe. There is no iron in the brain at birth; it increases progressively with aging. Knowledge of the distribution of brain iron should assist in elucidating normal anatomic structures and in understand­ ing neurodegenerative, demyelinating, and cerebrovascular disorders. It has been suggested that magnetic resonance (MR) , aside from producing exquisite anatomic images, may also provide unique biochemical information about brain function . Early attempts at Na-23 and P-31 imaging and spectroscopy have been promising but time-consuming.
    [Show full text]